Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
5
×
Tags
boston blog main
boston top stories
life sciences
5
×
national blog main
national top stories
san francisco blog main
5
×
san francisco top stories
boulder/denver blog main
boulder/denver top stories
deals
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
celgene
alnylam pharmaceuticals
biogen
biomarin pharmaceutical
cancer
crispr
drug prices
gene editing
gene therapy
hemophilia
ipo
medicare
What
bio
5
×
gene
5
×
roundup
drug
therapy
moves
patients
prices
race
advanced
alnylam’s
alzheimer’s
approval
aren’t
becker
bff
billions
companies
conference
create
crispr
deals
developers
devoted
diagnostic
different
disease
diseases
dollars
drugs
easl
eaton
editing
fail
fda
fix
form
healthcare
heats
help
Language
Current search:
bio
×
photo
×
" san francisco blog main "
×
gene
×
" life sciences "
×
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More